An Extracted Fraction of Pseudomonas Oleovorans Can Inhibit Viral Entry and RNA Replication of Hepatitis C Virus in Cell Culture

The emergence and distribution of Hepatitis C virus (HCV) infection is still considered as an unsolved problem. Due to side effects, many synthetic drugs have been avoided and replaced by new biologically derived ones. Aim of this study was to use Pseudomonas oleovorans’ extract as HCV viral replication inhibition agent in cell culture system. Several factors were studied and the optimum growth conditions were selected for maximum production of antiviral substance. Pseudomonas oleovorans’ extract was fractionated using different concentrations of chloroform: methanol on silica gel columns. Analysis of potent fraction by GC/MS showed of tetradecanoic and hexadecanoic acid methyl esters. The selected fraction was tested against HCV in vitro using two different protocols: viral attachment entry inhibition (Pre-incubation) and viral replication inhibition (Post infection). 0.1 µg / ml of the selected antiviral fraction resulted in inhibition of viral replication in Huh 7.5 cells. However, higher concentration of 100 µg / ml did not cause any viral inhibition. The selected bacterial fraction containing tetradecanoic acid and hexadecanoic acid methyl esters could be used as a promising candidate to inhibit viral HCV entry and replication of HCV

Impact of the COVID-19 pandemic on patients with paediatric cancer in low-income, middle-income and high-income countries: a multicentre, international, observational cohort study

OBJECTIVES: Paediatric cancer is a leading cause of death for children. Children in low-income and middle-income countries (LMICs) were four times more likely to die than children in high-income countries (HICs). This study aimed to test the hypothesis that the COVID-19 pandemic had affected the delivery of healthcare services worldwide, and exacerbated the disparity in paediatric cancer outcomes between LMICs and HICs. DESIGN: A multicentre, international, collaborative cohort study. SETTING: 91 hospitals and cancer centres in 39 countries providing cancer treatment to paediatric patients between March and December 2020. PARTICIPANTS: Patients were included if they were under the age of 18 years, and newly diagnosed with or undergoing active cancer treatment for Acute lymphoblastic leukaemia, non-Hodgkin's lymphoma, Hodgkin lymphoma, Wilms' tumour, sarcoma, retinoblastoma, gliomas, medulloblastomas or neuroblastomas, in keeping with the WHO Global Initiative for Childhood Cancer. MAIN OUTCOME MEASURE: All-cause mortality at 30 days and 90 days. RESULTS: 1660 patients were recruited. 219 children had changes to their treatment due to the pandemic. Patients in LMICs were primarily affected (n=182/219, 83.1%). Relative to patients with paediatric cancer in HICs, patients with paediatric cancer in LMICs had 12.1 (95% CI 2.93 to 50.3) and 7.9 (95% CI 3.2 to 19.7) times the odds of death at 30 days and 90 days, respectively, after presentation during the COVID-19 pandemic (p<0.001). After adjusting for confounders, patients with paediatric cancer in LMICs had 15.6 (95% CI 3.7 to 65.8) times the odds of death at 30 days (p<0.001). CONCLUSIONS: The COVID-19 pandemic has affected paediatric oncology service provision. It has disproportionately affected patients in LMICs, highlighting and compounding existing disparities in healthcare systems globally that need addressing urgently. However, many patients with paediatric cancer continued to receive their normal standard of care. This speaks to the adaptability and resilience of healthcare systems and healthcare workers globally

Twelve-month observational study of children with cancer in 41 countries during the COVID-19 pandemic

Childhood cancer is a leading cause of death. It is unclear whether the COVID-19 pandemic has impacted childhood cancer mortality. In this study, we aimed to establish all-cause mortality rates for childhood cancers during the COVID-19 pandemic and determine the factors associated with mortality